Glaucoma is a disease characterized by the combination of damage to the optic nerve and loss of visual field, primarily due to the death of retinal ganglion cells and gradual cupping of the optic nerve head [1] . Elevated intraocular pressure (IOP) is not only a main characteristic of glaucomatous disease, but also a significant etiologic factor. Although the exact etiology of glaucoma has not been completely understood, vascular factors that decrease ocular blood flow and result in subsequent dysfunction of neuroprotection are considered to be important factors in the development of the disease [2] [3] [4] [5] [6] . Since glaucoma is a multifaceted disease, there is significant research in process to develop the regimens that not only lower IOP, but also address other physiologic aspects of the disease, particularly in neuroprotective and vascular dysfunction. Current treatment strategies for glaucoma and ocular hypertension (OHT) are primarily aimed at decreasing elevated IOP. Topical beta-blockers are usually the first line of ocular hypotensive therapy. If target IOP is not reached after a period of monotherapy, switching treatment is used to obtain the desired IOP-decreasing effect, especially switching to drugs with different mechanisms [7] .
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Unoprostone isopropyl is a docosanoid derived from a metabolite of a primary prostaglandin, 13,14-dihydro-15-ketoprostaglandin. It was found to have a significant IOPlowering effect and was as effective as timolol in reducing IOP in primary open-angle glaucoma (POAG) [8, 9] . It acts by increasing uveoscleral outflow in a similar manner to latanoprost [10, 11] . Although the adjunctive use of unoprostone has a significant added IOP-decreasing effect in patients with POAG or OHT treated with beta-blockers alone, we used unoprostone alone (unoprostone isopropyl 0.12%, Rescula) as a replacement, not as adjunctive therapy, to evaluate its long-term efficacy and safety.
In this study, we collected topical beta-blocker-treated glaucoma patients with so-called long-term drift effect. Long-term drift is a phenomenon that occurs in patients with extended use of beta-blockers. There is a slow, but real upward "drift" in IOP, as the response to beta receptors is affected by constant exposure to an agonist. We evaluated the IOP-lowering effect and visual field preservation of Rescula as monotherapy to substitute beta-blockers with long-term drift effect in glaucoma patients.
PATIENTS AND METHODS
This study was prospectively carried out at the Kaohsiung Medical University Hospital, Taiwan. All patients enrolled in the study were followed in a glaucoma clinic and treated initially with beta-blockers, including 0.5% Bunolgan (levobunolol), 0.5% Timoptol XE (timolol), and 2% Arteoptic (carteolol) for at least 1 year. The types of glaucoma in these patients included POAG, chronic angle-closure glaucoma (CACG), normal tension glaucoma (NTG), and OHT. The reasons why beta-blockers were discontinued included elevated IOP (> 21 mmHg) with mild-to-moderate visual field loss (mean deviation of visual field defect between -3 and -25 dB ) and progressive visual field defect with normal IOP ( 21 mmHg). Patients received an alternative therapy with Rescula (unoprostone 0.12%) and were consecutively collected at the glaucoma clinic. Rescula was used twice a day, at 8 a.m. and 8 p.m., with the same frequency as betablockers. Baseline IOP was defined at the time when beta blockers were stopped. To prevent irreversible damage to the patients, we switched the eye drops without a washout period. Instead, we ignored the IOPs within the first month when two kinds of eye drops were overlapping. 
Statistical analysis
Statistical comparison of IOP reduction and visual field defect was performed by Student's paired t test.
RESULTS

Patient demographics
A total of 28 patients were enrolled in this study; Table 2 .
Changes in visual field defect
The mean deviation of visual field defect changed from -13.27 dB (baseline) to -10.64 dB (12 months after treatment with Rescula). There was no significant difference in the visual field defect (p = 0.098).
DISCUSSION
Rescula (unoprostone isopropyl) is generally prescribed to patients with open-angle glaucoma. In our study, Rescula was prescribed not only to patients with open-angle glaucoma, but also to patients with angle-closure glaucoma. The results revealed that Rescula is effective in both openangle (p = 0.00001) and angle-closure glaucoma (p = 0.02) after 12 months' follow-up. In general, beta-blockers have an excellent IOPdecreasing effect and are commonly used as the first-line IOP-lowering agent. Rescula is usually used as an adjunctive therapy to beta-blockers, but not as a replacement therapy. There were two reasons for using Rescula both as monotherapy and as a replacement of beta-blockers instead of adjunctive therapy. First, all our patients had used betablockers for at least 1 year. Initially, the IOP-lowering effect was good; however, IOP elevated gradually due to the long-term drift effect. In this situation, changing the eye drops or adding a second eye drop to lower IOP might be the next step. It was decided to stop the beta-blockers. Second, glaucoma is a chronic disease and requires longterm use of hypotensive medication. Thus, patient compliance is one of the major factors affecting long-term prognosis. The more convenient and simple the medication, the better is the compliance of patients. Monotherapy is still the best choice. As an alternative therapy, prostaglandin analog is usually the first choice of treatment. Although other prostaglandin analogs such as latanoprost may have better IOP-lowering effects than Rescula, Rescula has few of the local cosmetic side effects (such as conjunctival congestion and permanent melanin pigmentation of the eyelids and iris) that patients are seriously concerned about. Thus, Rescula was chosen as the alternative agent and the patients remained on monotherapy at the same frequency to observe if IOP would decrease as expected. The results revealed that Rescula can lower IOP effectively after switching from beta-blockers.
Unoprostone may have a neuroprotective effect because it can counteract endothelin-1-induced vasoconstriction in both animal and human models [12] [13] [14] , increase ocular blood flow and blood flow velocity in rabbits and humans [12, [15] [16] [17] [18] , and protect against ischemia and photoreceptor damage in rats [19] [20] [21] , as well as against glutamatemediated neuronal death in an in vitro model [22] . We evaluated the changes of visual field defect before and after Rescula treatment to ascertain whether Rescula can work as a preserver of the visual field. The results revealed a minimal improvement in visual field defect, but there was no significant difference (p = 0.098). Since visual field defect is generally irreversible, the preservation of visual defect after 12 months' follow-up in this study may suggest that 
